Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial
Cremolini, Chiara, Antoniotti, Carlotta, Rossini, Daniele, Lonardi, Sara, Loupakis, Fotios, Pietrantonio, Filippo, Bordonaro, Roberto, Latiano, Tiziana Pia, Tamburini, Emiliano, Santini, Daniele, PassJournal:
The Lancet Oncology
DOI:
10.1016/S1470-2045(19)30862-9
Date:
March, 2020
File:
PDF, 416 KB
2020